E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated | |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the efficacy of camostat mesylate in the treatment of SARS-CoV-2 infection in adult patients with confirmed COVID-19 not requiring initial hospitalization, , in terms of hospitalization needs, up to day 21 after randomization |
Evaluer l’efficacité du camostat mésylate dans le traitement de l’infection à SARS-CoV2 pour des patients adultes avec une maladie COVID-19 confirmée et ne nécessitant pas une hospitalisation initiale, en termes de nécessité d’hospitalisation pour la prise en charge COVID-19, entre J0 et J21. |
|
E.2.2 | Secondary objectives of the trial |
- Safety up to day 21 - Efficacy in terms of need for hospitalization for COVID-19 management, by independent blinded committee review - Overall clinical improvement at day 21 - Clinical efficacy in terms of intensive care needs, up to day 21 - Clinical efficacy in terms of time to hospitalization, up to day 21 - Clinical efficacy on respiratory functions, up to day 21 - Overall survival at day 21 and 90 after randomization - Patient-reported outcome on initial symptoms, up to day 21 - Virological, serological and immunological efficacy, up to day 21 - Renal complications, up to day 21 - Liver complications, up to day 14
|
- la tolérance du traitement, à 21 jours (J21) - l’efficacité en termes de nécessité d’hospitalisation pour la prise en charge COVID-19, selon une évaluation par un comité indépendant en aveugle du groupe de traitement de randomisation - l’amélioration clinique globale à J21 - l’efficacité clinique en termes de recours aux soins intensifs, entre J0 et J21 - l’efficacité clinique en termes de délai d’hospitalisation, entre J0 et J21 - l’efficacité clinique en termes d’impact sur la fonction respiratoire, entre J0 et J21 - la survie globale à J21 et J90 de l’inclusion - les symptômes, rapportés par les patients, entre J0 et J21 - l’efficacité virologique, sérologigue et immunologique entre J0 et J21 - les complications rénales, entre J0 et J21 - les complications hépatiques, entre J0 et J21
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Age > 18 y.o. 2) Laboratory confirmed SARS-CoV2 infection with mild COVID-19, fulfilling all the following criteria: - Positive SARS-CoV-2 RT-PCR nasal swab samples AND - Clinical symptoms and signs consistent with SARS-CoV2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgeusia…[WHO] 3) Informed consent to participate to the trial 4) Patients must be able and willing to comply with study visits and procedures
|
1) Age > 18 ans. 2) Infection SARS-CoV2 confirmée par prélèvement et modérée: - RT-PCR positive à SARS-CoV-2 par écouvillonnage nasal ET - symptômes et signes cliniques d’infection SARS-CoV2 infection incluant (mais non limité à): fièvre, signes d’infection respiratoire haute, signes digestifs, myalgies, anosmie, dysgeusie, … 3) Consentement informé à participer à l’essai 4) Patients en capacité et d’accord pour suivre les procédures de l’étude visites, prélèvements, traitement, etc.)
|
|
E.4 | Principal exclusion criteria |
1) Initial need for hospitalization for COVID-19 management : defined as any of the following severity criteria : respiratory rate > 24 /min at rest, Sp02 < 95% on room air, blood pressure < 100 mmHg, lethargy or unconsciousness, brutal overall deterioration or lethargy in the elderly (recommendations HCSP) all other reasons requiring immediate hospitalization left at the discretion of the physician 2) Pregnancy and breastfeeding 3) Participation to another interventional drug trial 4) Subject protected by law under guardianship or curatorship 5) Absence of health insurance 6) Known hypersensitivity to camostat mesylate 7) Known person sharing the same household already included in the study
|
1) Nécessité initiale d’hospitalisation pour COVID 19: selon les critères de sévérité suivants: fréquence respiratoire rate > 24 /min au repos, Sp02 < 95% en air ambiant, pression artérielle systolique < 100 mmHg, léthargie ou trouble de la conscience, détérioration globale et brutale ou léthargie pour les sujets âgés (recommandations HCSP) ; tout autre raison à la discrétion du médecin 2) Grossesse, allaitement 3) Participation à un autre essai médicamenteux 4) Patient sous tutelle ou curatelle 5) Patient non affilié à un régime de Sécurité Sociale 6) Allergie connue au camostat mesylate 7) Patient partageant son foyer avec une personne déjà inclus et participant à l’étude
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients hospitalized between day 1 and day 21, for COVID-19 deterioration. Criteria for hospitalization will be the presence of any of the following: respiratory rate > 24 /min at rest, Sp02 < 95% on room air, blood pressure < 100 mmHg, lethargy or unconsciousness, brutal overall deterioration or lethargy in the elderly [HCSP] and any all other reasons requiring hospitalization left at the discretion of the physician
|
Proportion de patients hospitalisés entre l’inclusion et J21, pour aggravation de la maladie COVID-19 Criteria for hospitalization will be the presence of any of the following: respiratory rate > 24 /min at rest, Sp02 < 95% on room air, blood pressure < 100 mmHg, lethargy or unconsciousness, brutal overall deterioration or lethargy in the elderly [HCSP] and any all other reasons requiring hospitalization left at the discretion of the physician
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |